Menu Search
Equities

Sedana Medical AB (publ)

7D2A:DUS

Sedana Medical AB (publ)

Actions
  • Price (EUR)0.981
  • Today's Change-0.012 / -1.21%
  • Shares traded--
  • 1 Year change-34.56%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 08:31 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sedana Medical AB (publ) is a Sweden-based medical technology company. It develops, markets and sales medical devices and conducts drug development for future projects around AnaConDa technology. The AnaConDa technology delivery enables of volatile anaesthetics to invasively ventilated patients. The products portfolio comprises disposable medical devices AnaConDa for administration of volatile anaesthetics, AnaConDa syringes, FlurAbsorb charcoal filters for removing halogenated hydrocarbon anaesthetic gases, different lines and connectors which can be used to connect the FlurAbsorb filter, adaptors, among others. The Company’s main shareholders are board members, Linc AB and Magiola Consulting AB.

  • Revenue in SEK (TTM)174.14m
  • Net income in SEK-57.24m
  • Incorporated2004
  • Employees78.00
  • Location
    Sedana Medical AB (publ)Vendevagen 89DANDERYD 182 32SwedenSWE
  • Phone+46 812405200
  • Fax+46 812405296
  • Websitehttps://sedanamedical.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.